Endocannabinoid system: Potential novel targets for treatment of schizophrenia

Neurobiology of Disease

Volumn 53, Issue , 2013, Pages 10-17

  Saito, Atsushi ^a,b   Ballinger, Michael D L ^a   Pletnikov, Mikhail V ^a   Wong, Dean F ^a   Kamiya, Atsushi ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cannabis; Endocannabinoid system; Environmental factor; Genetic risk factor; Schizophrenia

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABIS; DRINABANT; ENDOCANNABINOID;

BINDING AFFINITY; BINDING SITE; BRAIN DEVELOPMENT; BRAIN REGION; CANNABINOID RECEPTOR TYPE 1 GENE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG TARGETING; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; CANNABINOID RECEPTOR MODULATORS; DRUG DELIVERY SYSTEMS; ENDOCANNABINOIDS; HUMANS; MARIJUANA SMOKING; RECEPTORS, CANNABINOID; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84875086499     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.11.020     Document Type: Review

References (99)

1. Aguado T., et al. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J. Neurosci. 2006, 26:1551-1561.
2. Andreasson S., et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
3. Arseneault L., et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
4. Bangalore S.S., et al. Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr. Res. 2008, 99:1-6.
5. Barna I., et al. WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids. Behav. Pharmacol. 2007, 18:515-520.
6. Berghuis P., et al. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19115-19120.
7. Berghuis P., et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 2007, 316:1212-1216.
8. Berrendero F., et al. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 1999, 33:181-191.
9. Bisogno T., et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 2003, 163:463-468.
10. Black M.D., et al. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) 2011, 215:149-163.
11. Block R.I., et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000, 11:491-496.
12. Bromberg K.D., et al. Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science 2008, 320:903-909.
13. Cahn W., et al. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr. Res. 2004, 67:305-307.
14. Campolongo P., et al. Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4888-4893.
15. Caspi A., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
16. Chavarria-Siles I., et al. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147:279-284.
17. Da S., Takahashi R.N. SR 141716A prevents delta 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:321-325.
18. Deadwyler S.A., et al. Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes. Behav. Pharmacol. 2007, 18:571-580.
19. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
20. Devane W.A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
21. Di Forti M., et al. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 2009, 195:488-491.
22. Di Marzo V. Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat. Neurosci. 2011, 14:9-15.
23. Doherty J.L., et al. Recent genomic advances in schizophrenia. Clin. Genet. 2012, 81:103-109.
24. D'Souza D.C., et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
25. Eggan S.M., et al. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65:772-784.
26. Eggan S.M., et al. Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb. Cortex 2009, 20:1164-1174.
27. Eggan S.M., et al. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 2010, 35:2060-2071.
28. Ferrari F., et al. Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task. Pharmacol. Biochem. Behav. 1999, 64:555-561.
29. Freund T.F., et al. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
30. Giuffrida A., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
31. Glatt S.J., et al. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am. J. Psychiatry 2003, 160:469-476.
32. Han J., et al. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012, 148:1039-1050.
33. Harkany T., et al. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol. Sci. 2007, 28:83-92.
34. 2+ dependency for triggering retrograde endocannabinoid signal. Neuron 2005, 45:257-268.
35. Heifets B.D., Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 2009, 71:283-306.
36. Henquet C., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11.
37. Heyser C.J., et al. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 1993, 264:294-307.
38. Horti A.G., et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J. Nucl. Med. 2006, 47:1689-1696.
39. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
40. Jaaro-Peled H., et al. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci. 2009, 32:485-495.
41. Jung K.M., et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol. Pharmacol. 2005, 68:1196-1202.
42. Kamiya A., et al. DISC1 pathway in brain development: exploring therapeutic targets for major psychiatric disorders. Front. Psychiatry 2012, 3:25.
43. Kamprath K., et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J. Neurosci. 2006, 26:6677-6686.
44. Kano M., et al. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
45. Katona I., Freund T.F. Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 2012, 35:529-558.
46. Keimpema E., et al. Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol. Sci. 2011, 32:551-561.
47. Kilb W. Development of the GABAergic system from birth to adolescence. Neuroscientist 2012, 18:613-630.
48. Koethe D., et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J. Neural Transm. 2007, 114:1055-1063.
49. Koethe D., et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry 2009, 194:371-372.
50. Leweke F.M., et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 10:1665-1669.
51. Leweke F.M., et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 2007, 94:29-36.
52. Lichtman A.H., et al. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 1995, 119:282-290.
53. Maccarrone M., et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 2002, 15:1178-1186.
54. Maejima T., et al. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 2001, 31:463-475.
55. Mallet P.E., Beninger R.J. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide. Psychopharmacology (Berl) 1998, 140:11-19.
56. Marsicano G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
57. Mato S., et al. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur. J. Neurosci. 2003, 17:1747-1754.
58. Matsuda L.A., et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
59. Miettunen J., et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br. J. Psychiatry 2008, 192:470-471.
60. Monory K., Lutz B. Genetic models of the endocannabinoid system. Curr. Top. Behav. Neurosci. 2009, 1:111-139.
61. Mulder J., et al. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8760-8765.
62. Munro S., et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
63. Navarrete M., Araque A. Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 2010, 68:113-126.
64. Newell K.A., et al. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 2006, 172:556-560.
65. O'Donnell P. Adolescent maturation of cortical dopamine. Neurotox. Res. 2010, 18:306-312.
66. Ohno-Shosaku T., et al. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
67. Ohno-Shosaku T., et al. Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry into rat hippocampal neurons. J. Physiol. 2007, 584:407-418.
68. Ohno-Shosaku T., et al. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 2011, 18:119-132.
69. O'Tuathaigh C.M., et al. Chronic adolescent exposure to Delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
70. Ozaita A., et al. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J. Neurochem. 2007, 102:1105-1114.
71. Potvin S., et al. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr. Res. 2008, 100:242-251.
72. Rais M., et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry 2008, 165:490-496.
73. Robinson L., et al. WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. Behav. Brain Res. 2010, 208:584-592.
74. Rodriguez de Fonseca F., et al. Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 1993, 4:135-138.
75. Roser P., et al. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J. Biol. Psychiatry 2010, 11:208-219.
76. Rubino T., et al. The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox. Res. 2009, 15:291-302.
77. Rueda D., et al. The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J. Biol. Chem. 2002, 277:46645-46650.
78. Schneider M., Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003, 28:1760-1769.
79. Seifert J., et al. No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci. Lett. 2007, 426:29-33.
80. Steel R.W., et al. Learning impairment by Delta(9)-tetrahydrocannabinol in adolescence is attributable to deficits in chunking. Behav. Pharmacol. 2011, 22:837-846.
81. Sugiura T., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215:89-97.
82. Szeszko P.R., et al. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br. J. Psychiatry 2007, 190:230-236.
83. Terranova J.P., et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 1996, 126:165-172.
84. Tsai S.J., et al. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr. Genet. 2000, 10:149-151.
85. Tunbridge E.M., et al. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 2006, 60:141-151.
86. Ujike H., et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 2002, 7:515-518.
87. van Os J., et al. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156:319-327.
88. Varma N., et al. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 2001, 21. (RC188).
89. Varvel S.A., et al. Disruption of CB(1) receptor signaling impairs extinction of spatial memory in mice. Psychopharmacology (Berl) 2005, 179:863-872.
90. Varvel S.A., et al. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007, 32:1032-1041.
91. Williams E.J., et al. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 2003, 160:481-486.
92. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
93. Wilson W., et al. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J. Addict. Dis. 2000, 19:1-22.
94. Wong D.F., et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010, 52:1505-1513.
95. Wu C.S., et al. Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur. J. Neurosci. 2010, 32:693-706.
96. Zammit S., et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325:1199.
97. Zammit S., et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry 2007, 191:402-407.
98. Zanettini C., et al. Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front. Behav. Neurosci. 2011, 5:57.
99. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:355-360.